Clinical Trials

168 enrolled

Advanced Solid Tumor

NCT06779851 2026-04-22

SUMMIT-1

Phase 1 Terminated

20 enrolled

Advanced Solid Tumors

NCT07387068 2026-04-22

Trial to Evaluate the Safety and Preliminary Efficacy of GEN1079 in Participants With Advanced Solid Tumors

121 enrolled

Advanced Solid Tumors

NCT06480552 2026-04-21

An Open-label Dose Escalation/Expansion Trial to Evaluate the Safety and Anti-tumor Activity of TEV-56278 Alone or in Combination With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors

240 enrolled

Advanced Solid Tumors

NCT06532565 2026-04-21

Study of GS-2121 Given Alone or in Combination in Adults With Advanced Solid Tumors

154 enrolled

Advanced Solid Tumors

NCT07204340 2026-04-21

TLN-372 in Advanced KRAS Mutant Solid Tumors

240 enrolled

KRAS Mutant Solid Tumors

NCT07346846 2026-04-21

A Study of BGM-2121 in Patients With Advanced Solid Tumors

35 enrolled

Phase 1 Not yet recruiting

Advanced Solid Tumors

NCT07541534 2026-04-21

A Phase I Clinical Study of HLX316 in Participants With Advanced/Metastatic Solid Tumors

41 enrolled

Advanced/Metastatic Solid Tumors

NCT07541573 2026-04-21

Phase 1a/1b GTB-5550 in Advanced Solid Tumors

175 enrolled

Tri-specific Killer Engager

NCT04855656 2026-04-20

MYTHIC

464 enrolled

Advanced Solid Tumor

NCT05571839 2026-04-20

A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors

DermatologicGastrointestinalOther solid neoplasmThoracic

41 enrolled

Carcinoma, Non-Small-Cell Lung, Melanoma, Mesothelioma, Pancreatic Neoplasms, Colorectal Neoplasms

NCT06659341 2026-04-20

A Phase I Study of BAY3498264 Given Together With Sotorasib in Participants Who Have Advanced Solid Cancers With Specific Genetic Changes Called KRASG12C Mutation

104 enrolled

Advanced Solid Tumors Harboring KRAS G12C Mutation

NCT06892379 2026-04-20

A Study of HS-20110 in Participants With Advanced Solid Tumors

475 enrolled

Phase 1 Not yet recruiting

Solid Tumors

NCT07538479 2026-04-20

NIVALIS

24 enrolled

Solid Tumors

NCT07539285 2026-04-20

A Study of HDM2024 in Participants With Advanced Solid Tumors

63 enrolled

Advanced Solid Tumors

NCT03317743 2026-04-17

Study to Assess the Safety & Tolerability of NOV140101(IDX-1197) in Patients With Advanced Solid Tumors

Phase 1 Completed

32 enrolled

DermatologicHead & NeckOther solid neoplasmThoracic

Advanced Solid Tumors

NCT03881488 2026-04-17

Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies

Phase 1 Completed

100 enrolled

Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Melanoma, Mesothelioma, Neoplasm Metastasis, Small Cell Lung Carcinoma

NCT06307795 2026-04-17

A Study to Investigate ANS014004 in Participants With Locally Advanced or Metastatic Solid Tumors

63 enrolled

Locally Advanced or Metastatic Solid Tumors

NCT06597721 2026-04-17

ADCE-T02, a Tissue Factor Targeted Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours

210 enrolled

Advanced Solid Tumor

NCT07529535 2026-04-17

A First-in-Human Study of ALK-N001 for Injection in Patients With Advanced Solid Tumors

Phase 1 Suspended

16 enrolled

Advance Solid Tumors

NCT04241835 2026-04-16

A Study to Compare the Blood Levels and Safety of Tazemetostat in Participants With Advanced Cancer and Moderate/Severe Liver Impairment to Participants With Advanced Cancer and Normal Liver Function

Phase 1 Terminated

18 enrolled

Hepatic Impairment

NCT06066424 2026-04-16

Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Patients With Advanced Solid Tumors (TROPIKANA)

54 enrolled

Solid Tumors

NCT06082960 2026-04-16

Study of GS-9911 With or Without Antibody Treatment for Adults With Solid Tumors

45 enrolled

Solid Tumors

NCT06576037 2026-04-16

Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial Origin

128 enrolled

Solid Tumor

NCT07380334 2026-04-16

A Clinical Study on the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-1049 in Patients With Advanced Solid Tumors

200 enrolled

Phase 1 Not yet recruiting

Advanced Solid Tumor

NCT07533708 2026-04-16

A Phase I Clinical Study of HLX3902 in Patients With mCRPC and Other Advanced Tumours

48 enrolled

mCRPC or Advanced/Metastatic Solid Tumors

NCT05718895 2026-04-15

CLINCH

156 enrolled

Advanced/Metastatic Solid Tumors

NCT06233942 2026-04-15

Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors

308 enrolled

Advanced Solid Tumor

NCT06596473 2026-04-15

A Study of BG-C477 in Participants With Advanced Solid Tumors

310 enrolled

Advanced Solid Tumors

NCT07181681 2026-04-15

A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors

63 enrolled

Solid Tumors

NCT07226349 2026-04-15

A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors

105 enrolled

Advanced Solid Tumor

NCT07362888 2026-04-15

First-in-Human Study of ADCE-B05 in Patients With Advanced Solid Tumors

180 enrolled

Solid Tumors (Phase 1)

NCT07395258 2026-04-15

A Study to Test Different Doses of BI 3923948 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors)

60 enrolled

EndocrineNETOther solid neoplasmThoracic

Solid Tumors

NCT04375267 2026-04-14

LuPARP

Phase 1 Completed

18 enrolled

Mesothelioma, Thymoma, Neuroendocrine Tumors

NCT05071846 2026-04-14

MVX-ONCO-2 in Advanced Solid Tumors

6 enrolled

Solid Tumor, Adult

NCT05155332 2026-04-14

A Study to Test Different Doses of BI 1831169 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors)

190 enrolled

Solid Tumors

NCT05430373 2026-04-14

GT101 Injection for the Treatment of Metastatic or Recurrent Solid Tumors

31 enrolled

Solid Tumors, Adult

NCT06220864 2026-04-14

SNV1521 in Participants With Advanced Solid Tumors

400 enrolled

Advanced Solid Tumor

NCT06718621 2026-04-14

A Study of BL-M08D1 in Patients With Locally Advanced or Metastatic Solid Tumors

22 enrolled

Solid Tumor

NCT01434316 2026-04-13

Veliparib and Dinaciclib in Treating Patients With Advanced Solid Tumors

121 enrolled

Advanced Malignant Solid Neoplasm

NCT02453620 2026-04-13

Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer

BreastOther solid neoplasm

57 enrolled

Anatomic Stage III Breast Cancer AJCC v8

NCT04491942 2026-04-13

Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer

BreastGenitourinaryGynecologicOther solid neoplasmThoracic

74 enrolled

Mesothelioma, Malignant, Uterine Cervical Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Penile Neoplasms, Triple Negative Breast Neoplasms

NCT05879627 2026-04-13

To Evaluate the Safety, Tolerance and Pharmacokinetics of BAT8007 for Injection in Patients With Advanced Solid Tumors

Phase 1 Terminated

93 enrolled

Advanced Solid Tumors

NCT06143774 2026-04-13

Study of TRX-920 for Patients With Advanced Solid Tumors

30 enrolled

Advanced Solid Tumor

NCT06352359 2026-04-13

Safety, Pharmacokinetics (PK), and Efficacy of ONC 841 in Advanced Solid Tumors

72 enrolled

Advanced Solid Tumor

NCT06573294 2026-04-13

Trial to Assess the Safety and Antitumor Activity of GEN1057 in Malignant Solid Tumors

45 enrolled

Advanced Malignant Solid Tumors

NCT06960395 2026-04-13

Safety and Preliminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

450 enrolled

Solid Tumor Malignancies

NCT07040943 2026-04-13

Clinical Trial of IL - 22BP Safety, Tolerability, and Antitumor Activity in Refractory Solid Tumors.

6 enrolled

Refractory Malignant Solid Tumors

NCT07223125 2026-04-13

A Study of JNJ-89862175 for Treatment of Advanced Solid Tumors

360 enrolled